Our state-of-the-art plant is cGMP-certified and has been licensed by the Belgium Regulatory Agency for the manufacturing of ATMP products. The 1200m2 space is set up to manage multiple production and development projects simultaneously. The facility is designed for both clinical and commercial production.
CureCell (MaSTherCell Korea) is a Korean based company with a particular focus on developing innovative regenerative therapies for both the Korean and international markets. Together, with promising in-house research programs, the foreign technologies are currently under development for fastest growing Asian market well beyond the Korean market offering the most favorable environment for the regenerative medicine industry in the world. Through close collaboration with leading medical and academic facilities, CureCell is accelerating the development of foreign technologies in Korea and is well positioned in expanding international markets for Korean technologies. Orgenesis and CureCell created a Joint Venture for Contract Development and Manufacturing of Cell Therapy Products in South Korea.
Atvio-Biotech (MaSTherCell Israel) is a CDMO focused on process development, upscaling, automation and virus manufacturing for cell therapies. The company is located in Haifa utilizing the unique Israeli innovative ecosystem and highly experienced talent members. The center provides cell therapy cGMP manufacturing, process development capabilities and expertise, custom engineering, unique platform design and optimization.
The company has 700 sqm2 of labs and clean room space resulting in an efficient and unique environment for cell therapy development.